Macrolides versus quinolones in Legionella pneumonia: Results from the Community-Acquired Pneumonia Organization international study

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 4, 2010, Pages 495-499

  Griffin, Allen T ^a   Peyrani, P ^a   Wiemken, T ^a   Arnold, F ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Legionella; Macrolides; Quinolones

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; LEVOFLOXACIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM DETECTION; CLINICAL ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; FEMALE; HOSPITAL ADMISSION; HUMAN; LEGIONELLA; LEGIONNAIRE DISEASE; LENGTH OF STAY; MALE; NONHUMAN; PRIORITY JOURNAL; SPUTUM CULTURE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHI-SQUARE DISTRIBUTION; CLARITHROMYCIN; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LEGIONELLA PNEUMOPHILA; LEGIONNAIRES' DISEASE; LENGTH OF STAY; MALE; OFLOXACIN; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 77950322812     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Neil K, Berkelman R. Increasing incidence of legionellosis in the United States. 1990-2005: changing epidemiologic trends. Clin Infect Dis 2008; 47: 591-599.
2. Reda C, Quaresima T, Pastoris, M. In-vitro activity of six intracellular antibiotics against Legionella pneumophila strains of human and environmental origin. J Antimicrob Chemother 2005; 33: 757-764.
3. Blázquez-Garrido R, Espinosa Parra F, Alemany Francés L, et al. Antimicrobial chemotherapy for Legionnaires' disease: levofloxacin versus macrolides. Clin Infect Dis 2005; 40: 800-806.
4. Mykietiuk A, Carratalá J, Fernández-Sabé N, et al. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy. Clin Infect Dis 2005; 40: 794-799.
5. Falco V, Molina I, Juste C, et al. [Treatment for Legionnaires' disease. Macrolides or quinolones?] Enferm Infecc Microbiol Clin 2006; 24: 360-364. [Spanish]
6. Howden B, Stuart R, Tallis G, Bailey M, Johnson P D. Treatment and outcome of 104 hospitalized patients with Legionnaires' disease. Intern Med J 2003; 33: 484-488.
7. Sabria M, Pedro-Botet M, Gomez J, et al. Legionnaires' Disease Therapy Group. Fluoroquinolones vs macrolides in the treatment of Legionnaires' disease. Chest 2005; 128: 1401-1405.
8. Haranaga S, Tateyama M, Higa F, et al. Intravenous ciprofloxacin versus erythromycin in the treatment of Legionella pneumonia. Intern Med J 2007; 46: 353-357.
9. Fine M, Auble T, Yealy D, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250.
10. Lim W, van der Eerden M, Laing R, et al. Defi ning community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377-382.
11. Mandell L, Wunderink R, Anzueto A, et al. Infectious Disease Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl 2): S27-S72.
12. Kraus C, Zalkikar J, Powers J. Levofloxacin and macrolides for treatment of Legionnaires' disease: multiple comparisons give few answers. Clin Infect Dis 2005; 41: 416.